Table 5.

Net Effects and Cost-effectiveness Results of a Supplemental PCV15 dose, among Children Aged 2 years and Older who have Already Received a Full PCV13 series, by Specific Age Cohort.

Model results	Age 2 years	Age 3 years	Age 4 years	Age 5 years
Cases prevented
AOM	26,110	18,349	9681	0
Tympanostomy tube insertion	2089	1468	774	0
Outpatient Pneumonia	677	503	438	391
Inpatient Pneumonia	218	158	135	117
Deaths due to Pneumonia	1	1	1	1
IPD Non-Meningitis	39	34	27	24
IPD Meningitis	8	7	6	6
Deafness	1	1	0	0
Disability	1	1	1	1
Deaths due to IPD	3	2	2	2
QALYs gained	158	129	101	77
Life-years gained	120	104	90	82
Savings [Additional costs], $ millions
Total Cost	[409]	[413]	[417]	[421]
Medical Costs	17	13	9	4
Nonmedical Costs	8	6	4	1
Vaccine Costs	[434]	[432]	[429]	[426]
Cost-effectiveness Ratios ($)
Cost/QALY	2,595,642	3,198,991	4,136,984	5,490,205
Cost/Life-year	3,402,561	3,952,575	4,622,636	5,111,949

Abbreviations: PCV13: 13-valent pneumococcal conjugate vaccine, PCV15: 15-valent pneumococcal conjugate vaccine, AOM: acute otitis media, IPD: invasive pneumococcal disease, QALY: Quality-adjusted life-year. All outcomes, QALYs gained, life-years gained, and costs were discounted. All savings [costs] are reported in $US2021.